The Latest Regenerative Medicine Articles from Streetwise Reports


Regenerative Medicine Firm Reports Early Results from COVID-19 Trials

Research Report
  ()
Pluristem Therapeutics' coronavirus clinical studies and financing are discussed in a Dawson James report. read more >

Mesoblast Shares Soar 120% After Reporting 83% Survival Rate in COVID-19 Patients with ARDS

  ()
Shares of Mesoblast more than doubled and set a new 52-week high price after the company reported that it achieved a 83% survival rate in New York ventilator-dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome who were treated with its allogeneic cell therapy remestemcel-L. read more >

Biotech to Test Stem Cell Product in COVID-19-Caused Acute Respiratory Distress

Research Report
  ()
A description of Mesoblast's multi-site clinical trial and possible implication for the therapeutic are provided in an H.C. Wainwright & Co. report. read more >

Three COVID-19 Patients Treated with PLX Cells

Research Report
  ()
Two programs, one new and the other ongoing, involving Pluristem Therapeutics' regenerative products are reviewed in a Dawson James report. read more >

'Stay Tuned for Data' from Regenerative Medicine Firm with 'Blockbuster Opportunity'

Research Report
  ()
The compelling aspects of this life sciences story are presented in a Dawson James report. read more >
Showing Results: 1 to 5 of 5

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe